Radiation Treatment for Breast and Prostate

Cancer

Chris Premo, MD Radiation Oncology Madigan Army Medical Center

Disclosures

Employed by the US Army. The slides and discussion are my own views/opinion and do not represent the opinion/views of the government, DoD, US Army, or Madigan Army Medical Center.

Outline

History of radiation

- Brief physics and biology review
- Conditions treated with radiation therapy
- Logistics of radiation therapy typical course of therapy
- Radiation planning –various techniques and considerations
- Short term side effects
- Long term side effects
- Follow up/surveillance

History of Radiation

- Xrays discovered in 1895 by Wilhelm Roentgen
- One of the first pictures of an xray was of his wife's hand.
- Within 3 years radiation was used to treat cancers



History of Radiation

Early uses of radiation:

- Skin conditions such as acne
- Removal of unwanted hair
- Treatment of tonsils and adenoids
- Scalp treatment for ringworm
- Treatment of enlarged thymus

RADIUM THERAPY

The only scientific apparatus for the preparation of radio-active water in the hospital or in the patient's own home.

This apparatus gives a high and measured dosage of radio-active drinking water for the treatment of gout, rheumatism, arthritis, neuralgia, sciatica, tabes dorsalis, catarrh of the antrum and frontal sinus, arterio-sclerosis, diabetes and glycosuria, and nephritis, as described in

Dr. Saubermann's lecture before the Roentgen Society, printed in this number of the "Archives."

DESCRIPTION.

The perforated ex rthenware "activator" in the glass jar contains an insoluble preparation impregnated with radium. It continuously emits radium emanation at a fixed rate, and keeps the water in the jar always charged to a fixed and measureable strength, from 5,000 to 10,000 Maché units per litre per diem.

> RADIUM LIMITED, MORTIMER STREET, LONDON, W





Radiation Physics



Radiation Physics

Common types of radiation used for therapy:

Photon

Electron

Proton

Neutron

Carbon ion

Radioisotopes

Radiobiology

- Radiation causes cell damage by 2 main mechanisms which ultimately lead to cell death via apoptosis or, more commonly, during mitosis
 - Directly causes double stranded DNA breaks – 1/3
 - Generates free radicals in cells which then cause DNA damage – 2/3
- Normal cells can repair radiation damage within 6 hours



		1	les Females		
Prostate	174,650	20%	Breast	268,600	30%
Lung & bronchus	116,440	13%	Lung & bronchus	111,710	13%
Colon & rectum	78,500	9%	Colon & rectum	67,100	8%
Urinary bladder	61,700	7%	Uterine corpus	61,880	7%
Melanoma of the skin	57,220	7%	Melanoma of the skin	39,260	4%
Kidney & renal pelvis	44,120	5%	Thyroid	37,810	4%
Non-Hodgkin lymphoma	41,090	5%	Non-Hodgkin lymphoma	33,110	4%
Oral cavity & pharynx	38,140	4%	Kidney & renal pelvis	29,700	3%
Leukemia	35,920	4%	Pancreas	26,830	3%
Pancreas	29,940	3%	Leukemia	25,860	3%
All Sites	870,970	100%	All Sites	004 400	40.00/
				891,480	1007
ated Deaths			lles Females		
	76,650			66,020	23%
ated Deaths			lles Females		
ated Deaths Lung & bronchus	76,650	24%	Iles Females	66,020	23%
ated Deaths Lung & bronchus Prostate	76,650 31,620	24% 10%	Iles Females Lung & bronchus Breast	66,020 41,760	23% 15%
Lung & bronchus Prostate Colon & rectum Pancreas	76,650 31,620 27,640	24% 10% 9%	Iles Females Lung & bronchus Breast Colon & rectum	66,020 41,760 23,380	23% 15% 8%
Lung & bronchus Prostate Colon & rectum Pancreas	76,650 31,620 27,640 23,800	24% 10% 9% 7%	Lung & bronchus Breast Colon & rectum Pancreas	66,020 41,760 23,380 21,950	23% 15% 8% 5%
ated Deaths Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct	76,650 31,620 27,640 23,800 21,600	24% 10% 9% 7% 7%	Iles Females Lung & bronchus Breast Colon & rectum Pancreas Ovary	66,020 41,760 23,380 21,950 13,980	23% 15% 8%
Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct Leukemia	76,650 31,620 27,640 23,800 21,600 13,150	24% 10% 9% 7% 7% 4%	Iles Females Lung & bronchus Breast Colon & rectum Pancreas Ovary Uterine corpus	66,020 41,760 23,380 21,950 13,980 12,160	23% 15% 8% 5% 4%
ated Deaths Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct Leukemia Esophagus	76,650 31,620 27,640 23,800 21,600 13,150 13,020	24% 10% 9% 7% 7% 4% 4%	Iles Females Lung & bronchus Breast Colon & rectum Pancreas Ovary Uterine corpus Liver & intrahepatic bile duct	66,020 41,760 23,380 21,950 13,980 12,160 10,180	23% 15% 8% 5% 4%
nated Deaths Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct Leukemia Esophagus Urinary bladder	76,650 31,620 27,640 23,800 21,600 13,150 13,020 12,870	24% 10% 9% 7% 4% 4% 4%	Iles Females Lung & bronchus Breast Colon & rectum Pancreas Ovary Uterine corpus Liver & intrahepatic bile duct Leukemia	66,020 41,760 23,380 21,950 13,980 12,160 10,180 9,690	23% 15% 8% 5% 4% 3%

Siegal R et al. CA Cancer J Clin 2019

Conditions Treated With Radiation

Cancerous:

- Brain tumors
- Head/Neck cancers
- Breast cancer –typically used after surgery to reduce the risk of recurrence
- Lung cancer
- Gastrointestinal esophagus, stomach, pancreas, rectum, anus
- GU bladder, prostate used as definitive treatment or after surgery to reduce the chance of recurrence.
- ► Gyn endometrial, cervical, vulvar
- Soft tissue tumors sarcomas
- Skin cancer

Conditions Treated With Radiation

Benign conditions

- Heterotopic ossification prevention
- Dupuytren's/Ledderhose disease
- Plantar Fasciitis
- Keloids
- Pigmented villonodular synovitis (PVNS)
- Pterygium
- Benign tumors
- Graves' ophthalmopathy
- Peyronie's disease
- Trigeminal neuralgia

Logistics of Radiation Therapy

- CT simulation "dry run" or planning scan
- ► Radiation planning 1-2 weeks
- Treatment typically daily treatments, M-F, for several weeks
 - Breast cancer: 1-6 weeks
 - Prostate cancer: 1-8 weeks
- Treatment generally takes 10-15 minutes a day
- In general, radiation therapy is very safe and well tolerated with low risk of severe complications
- Many patients can work full time and exercise during radiation therapy i.e. minimal disruption to their daily activities

CT Simulation/Radiation Planning Scan









Patient position FFS

Patient position FFS



Treatment Techniques for Breast Cancer

- Whole breast radiation is standard for most patients
- Partial breast radiation for select women





4. Removal After the final treatment, the applicator is collapsed and easily removed.

Radiation Techniques for Prostate Cancer

External beam radiation therapy for 1-8 weeks





Radiation Techniques for Prostate Cancer

Brachytherapy



Short-Term Side Effects

Side effects from radiation are limited to the area treated

Breast Cancer –

- Fatigue/tiredness
- Skin redness, darkening, desquamation (peeling), pain/discomfort on the skin
- Fullness/tightness in the breast/chest wall

Prostate Cancer –

- Fatigue/tiredness
- Bladder: urinary frequency, urgency, pain with urination
- Bowel: soft/loose stools or diarrhea



Breast Cancer

- Mild-moderate cosmetic changes. Majority of women report good-excellent cosmetic outcome
- Residual skin darkening or telangiectasias (visible red blood vessels)
- Breast pain, swelling, increase/decrease in breast size
- Rib fracture
- Lung inflammation (<1%)</p>
- Heart disease rare, dose dependent
- Radiation-related cancer (<1%) develops years later</p>
- Lymphedema (lymph node dissection is biggest risk) dependent on surgery, BMI/weight, whether the lymph nodes were treated with radiation, etc.
- Radiation can increase complications of future surgeries on the treated side

	Moderate or marked events (n/patients; %)	Estimated proportion of patients with event by 5 years (%; 95% CI)	Estimated proportion of patients with event by 10 years (%; 95% Cl)	Crude hazard ratio (95% Cl)	p value*
Breast s	nrinkage†				
50 Gy	256/1003 (25.5%)	15.8% (13.6-18.3)	31.2% (27.9-34.9)	1.00	
40 Gy	221/1006 (22.0%)	11.4% (9.5–13.6)	26.2% (23.1-29.6)	0.80 (0.67-0.96)	0.015
Breast i	nduration (tumour	bed)†			
50 Gy	153/1003 (15.3%)	12.1% (10.2-14.4)	17·4% (14·9–20·3)	1.00	
40 Gy	129/1006 (12.8%)	9.6% (7.9-11.6)	14.3% (12.1-16.9)	0.81 (0.64-1.03)	0.084
Telangi	ctasia				
50 Gy	52/1081 (4.8%)	3.8% (2.8–5.2)	5.8% (4.4-7.7)	1.00	
40 Gy	34/1094 (3.1%)	1.8% (1.1-2.8)	4·2% (2·9-5·9)	0.62 (0.40-0.96)	0.032
Breast	edema†				
50 Gy	86/1003 (8.6%)	8·1% (6·6–10·1)	9.0% (7.3-11.0)	1.00	
40 Gy	49/1006 (4.9%)	4·7% (3·5–6·2)	5.1% (3.9-6.7)	0.55 (0.39-0.79)	0.001
Shoulde	r stiffness‡				
50 Gy	4/73 (5.5%)	2·9% (0·7–11·0)	8·2% (2·9-21·8)	1.00	
40 Gy	3/81 (3.7%)	3·1% (0·8–11·9)	3·1% (0·8–11·9)	0.76 (0.17-3.39)	0.71
Arm oe	lema‡				
50 Gy	7/73 (9.6%)	6·0% (2·3–15·3)	13·5% (6·4-27·0)	1.00	
40 Gy	3/81 (3.7%)	2.8% (0.7-10.7)	4.7% (1.5-14.0)	0.42 (0.11-1.63)	0.21
Other					
50 Gy	77/1082 (7.1%)	5.6% (4.3-7.2)	8.1% (6.5-10.2)	1.00	
40 Gy	53/1095 (4.8%)	3.3% (2.4-4.6)	6.4% (4.8-8.4)	0.65 (0.46-0.93)	0.018

*Assessed by Wald test compared with 50 Gy. †Only assessed in women who had breast-conserving surgery. ‡Restricted to women who received lymphatic radiotherapy (to axilla or supraclavicular fossa).

Table 5: Physician-assessed normal tissue effects by fractionation schedule in START-B

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials

Joanne S Haviland, J Roger Owen, John A Dewar, Rajiv K Agrawal, Jane Barrett, Peter J Barrett-Lee, H Jane Dobbs, Penelope Hopwood, Pat A Lawton, Brian J Magee, Judith Mills, Sandra Simmons, Mark A Sydenham, Karen Venables, Judith M Bliss*, John R Yarnold*, on behalf of the START Trialists' Group†

	START-A			START-B				
	50 Gy (n=749)	41.6 Gy (n=750)	39 Gy (n=737)	Total (n=2236)	50 Gy (n=1105)	40 Gy (n=1110)	Total (n=2215)	
Symptomatic rib fracture*								
Reported	5 (0·7%)	8 (1.1%)	9 (1.2%)	22 (1.0%)	17 (1.5%)	24 (2·2%)	41 (1 ·9%)	
Confirmed†	0	0	1(0.1%)	1 (<0.1%)	3 (0.3%)	3 (0.3%)	<mark>6 (0·3%)</mark>	
Symptomatic lung fibr								
Reported	6 (0.8%)	9 (1.2%)	8 (1.1%)	23 (1.0%)	19 (1·7%)	19 (1.7%)	38 (1.7%)	
Confirmed†	0	2 (0.3%)	1(0.1%)	3 (0.1%)	2 (0.2%)	8 (0.7%)	10 (0.5%)	
Ischaemic heart disease								
Reported	14 (1·9%)	11 (1.5%)	8 (1.1%)	33 (1·5%)	23 (2·1%)	17 (1·5%)	40 (1.8%)	
Confirmed†								
Total	7 (0.9%)	5 (0.7%)	<mark>6 (0·8%)</mark>	18 (0·8%)	16 (1·4%)	<mark>8 (0.7%)</mark>	24 (1.1%)	
Left sided	<mark>4 (0·5%)</mark>	1 (0·1%)	4 (0.5%)	9 (0·4%)	5 (0.5%)	4 (0·4%)	9 (0·4%)	
Brachial plexopathy	0	1 (0.1%)	0	1 (<0.1%)	0	0	0	

Data are n (%). *Reported cases include seven after trauma (five in START-A, two in START-B), and ten after metastases (five in START-A and five in START-B). †After imaging and further investigations. ‡26 patients in START-A and 22 in START-B had pre-existing heart disease at enrolment and were excluded.

Table 3: Incidence of other late adverse effects according to fractionation schedule

Prostate Cancer:

- Bladder symptoms: ~10-15% risk of mild-moderate persistent urinary bother symptoms such as frequency or urgency. May require medications. Incontinence is unlikely and not an expected complication.
 - More severe complications like persistent hematuria (blood in the urine) or urinary stricture is ~1-3%
- Bowel symptoms: ~ 5% risk of bothersome rectal/bowel issues such as diarrhea, urgency with bowel movements, blood in the stool, etc
 - More severe complications are rare
- Erectile dysfunction/sexual health: worsening erectile function in about 30-50% of patients over a few years.



Fig. 2. The cumulative incidence of grade ≥ 1 (A) and ≥ 2 (B) bowel toxicity and grade ≥ 1 urinary incontinence (C) and grade ≥ 2 urinary toxicity (D). *Abbreviations:* CI = confidence interval; HR = hazard ratio.



(A) as a function of treatment arm. Data presented as mean ± standard error of the mean. The proportion of patients with detectable changes in bowel quality of life at the 5-point (B) or 10-point (C) threshold. Abbreviations: CI = confidence interval; MID = minimally important difference; OR = odds ratio.

(A) as a function of treatment arm. Data presented as mean \pm standard error of the mean. The proportion of patients with detectable changes in bowel quality of life at the 6-point (B) or 12point (C) threshold. Abbreviations: CI = confidence interval; MID = minimally important difference; OR = odds ratio.

- Control

- Spacer

36

36

36

15

- Control-MID

- Spacer-MID

15

- Control-2x MID

15

Hamstra DA et al. IJROBP 2017

Onset of Symptoms

Breast Cancer:

- At 1 month post treatment most side effects have resolved.
- Skin darkening can linger for months.
- Breast edema, telangiectasias, and fibrosis can occur months to several years after treatment.
- Lymphedema may occur months to several years later
- Radiation pneumonitis/lung inflammation typically 6 weeks to 6 months after treatment
- Heart disease typically years later
- Radiation-related cancer many years later

Onset of Symptoms

Prostate Cancer



Figure 4: Acute RTOG toxicity by timepoint and randomised treatment group

(A) Prevalence of bowel toxicity and (B) prevalence of bladder toxicity. RTOG=Radiation Therapy Oncology Group. Grade 1+=grade 1 or worse adverse event. Grade 2+=grade 2 or worse adverse event. Grade 3+=grade 3 or worse adverse event.

Treatment/Management Options

Breast Cancer:

- Skin Care:
 - Erythema/redness moisturizing creams such as A&D creams, eucerin, aquaphor, biafene, radiaguard, hydraguard, aloe, calendula, etc.
 - Desquamation A&D, zinc oxide, bacitracin, medihoney, silvadene
 - Mometasone steroid cream shown to reduce rates of desquamation
 - Avoid skin friction/irritation
 - Non-stick dressings
- Fibrosis or lymphedema:
 - Physical therapy
 - Lymphedema therapy
 - Massage therapy
 - Trental/Vit E for 6 months
- Chronic pain
 - OTC pain medications, gabapentin

Treatment/Management Options

Prostate Cancer

- During treatment:
 - Medications such as tamsulosin, NSAIDS, tolterodine, or pyridium can be tried for urinary symptoms.
 - Dietary changes or medications such as Imodium, proctofoam, or Anusol can be tried for bowel symptoms
- Long-term complications:
 - Medications to help relax the bladder or improve urinary flow may be required
 - Intermittent use of Imodium
 - Radiation proctitis may require topical treatments from a gastroenterologist for rectal bleeding or may require medications such as sucralfate or steroid enema
 - Erectile dysfunction: Medications, vacuum devices, rings, injections, surgery, etc

Ways to Minimize Complications

Breast Cancer:

- Breath hold when treating left side
- Hypofractionated treatment
- Partial breast radiation?
- Minimizing "hot spots" of radiation during planning
- Proton therapy?

Prostate Cancer:

- Use advanced radiation techniques
- Daily image-guidance with fiducials, beacons, CT scans, etc
- Rectal spacers decreased rates of rectal irritation and erectile dysfunction.
- Maintain full bladder and empty rectum from treatment

Efficacy of Treatment

Breast Cancer:

- Locoregional recurrence rates are LOW in the modern era. For stage I-III breast cancer treated with lumpectomy/mastectomy, radiation, +/- systemic therapy such as chemo or anti-estrogen therapy the recurrence at 10 years is ~4% (in the breast or lymph nodes)
- Prostate Cancer treated curatively with radiation: 5-10 year biochemical control (PSA remains low)
 - Many variables but risk group most important predictor:
 - ▶ Low risk >90%
 - Intermediate ~80-90%
 - ▶ High risk 60-80%
 - Following radiation, it can take several years for the PSA to nadir

Surveillance

Breast Cancer

- Exam at least every 6 months for 5 years and then annually
- Mammogram annually
- Breast MRI in select women
- CT, bone scan, or PET/CT scan as needed.

Prostate Cancer

- PSA every 6 months for 5 years and then annually
- Imaging studies/scans as clinically indicated

Salvage Treatment

- What if my cancer comes back? Can I get more radiation?
- **Breast cancer:**
 - If cancer returns after lumpectomy and radiation generally the recommendation is for a mastectomy
 - If cancer returns after mastectomy surgical excision if possible followed by radiation if no prior radiation.
- Prostate cancer:
 - PSA rise of > 2 above the nadir is technically considered a cancer recurrence after definitive radiation.
 - Don't be fooled by a PSA "bounce" a temporary rise in PSA within a couple years of radiation.
 - Surgery, cryotherapy, HIFU, brachytherapy, systemic therapy such as androgendeprivation therapy/anti-testosterone therapy.

Surgery After Radiation

Breast:

- Radiation can complicate reconstruction surgery or increase the risk of fibrosis/scaring or cause delayed/complicated healing.
 - Reconstruction is commonly done after radiation surgeons may wait up to a year after radiation before completing reconstruction surgery.
- Radiation can be delivered with a tissue expander/implant in place.

Prostate:

- Surgery can be performed after radiation but it's more complicated and there is a higher risk of post-op complications.
- Surgery is rarely needed after radiation therapy.

Questions?

